# Cardiology Department - Clinical Policy Document

> **⚠️ MEDICAL EXPERT REVIEW REQUIRED**
> This policy document defines clinical protocols and decision-making frameworks for cardiology consultations. All protocols must be validated by board-certified cardiologists and aligned with current ACC/AHA guidelines.

---

## Document Control

| Field | Value |
|-------|-------|
| **Department** | Cardiology |
| **Version** | 1.0 (Draft) |
| **Effective Date** | Pending Review |
| **Review Cycle** | Annually |
| **Approved By** | ⚠️ Pending |
| **Last Updated** | 2025-03-09 |

---

## 1. Clinical Philosophy & Scope

### 1.1 Mission Statement
The Cardiology Department provides evidence-based cardiovascular consultation services using AI-assisted clinical decision support while maintaining physician oversight and patient safety as paramount priorities.

### 1.2 Scope of Practice
This policy covers:
- Hypertension evaluation and management
- Arrhythmia assessment (basic rhythm interpretation)
- Cardiovascular risk assessment
- Ischemic heart disease evaluation (initial assessment)
- Heart failure management (basic classification)
- Preventive cardiology (lipid management, risk factor modification)

**Out of Scope** (requires specialist referral):
- Advanced cardiac imaging interpretation (echo, CT, MRI)
- Complex arrhythmia management (ablation, device programming)
- Interventional cardiology procedures
- Advanced heart failure therapies
- Pediatric cardiology (under 12 years)
- Adult congenital heart disease

### 1.3 Clinical Decision Support Principles
1. **Augmentation, Not Replacement**: AI tools support, not replace, clinical judgment
2. **Evidence-Based**: All recommendations grounded in current ACC/AHA guidelines
3. **Safety First**: When uncertain, recommend specialist consultation
4. **Transparency**: Clearly communicate tool limitations and confidence levels
5. **Documentation**: All tool use and recommendations must be documented

---

## 2. Patient Evaluation Protocols

### 2.1 Initial Consultation Workflow

```
┌─────────────────────────────────────────────────────────────┐
│                    PATIENT PRESENTATION                      │
└──────────────────────┬──────────────────────────────────────┘
                       │
                       ▼
┌─────────────────────────────────────────────────────────────┐
│  STEP 1: Gather Basic Information                           │
│  • Patient demographics (age, sex, race)                    │
│  • Chief complaint                                          │
│  • Vital signs (BP, HR, RR, Temp, O2 sat)                   │
│  • Past medical history                                     │
│  • Current medications                                      │
└──────────────────────┬──────────────────────────────────────┘
                       │
                       ▼
┌─────────────────────────────────────────────────────────────┐
│  STEP 2: Risk Stratification                                │
│  • Blood pressure classification                            │
│  • ASCVD risk calculation (if age 40-75)                   │
│  • Review available lab results                             │
│  • Assess symptoms (chest pain, palpitations, dyspnea)      │
└──────────────────────┬──────────────────────────────────────┘
                       │
                       ▼
┌─────────────────────────────────────────────────────────────┐
│  STEP 3: Determine Urgency                                  │
│  • Emergent: Hypertensive crisis, ACS symptoms             │
│  • Urgent: Uncontrolled HTN, new arrhythmias               │
│  • Routine: Stable conditions, preventive care            │
└──────────────────────┬──────────────────────────────────────┘
                       │
                       ▼
┌─────────────────────────────────────────────────────────────┐
│  STEP 4: Formulate Management Plan                          │
│  • Lifestyle modifications                                   │
│  • Pharmacological interventions                             │
│  • Diagnostic testing recommendations                        │
│  • Follow-up planning                                       │
│  • Specialist referral if indicated                         │
└─────────────────────────────────────────────────────────────┘
```

### 2.2 Mandatory Documentation Elements

Every consultation must include:
- [ ] Patient identifiers (de-identified for AI systems)
- [ ] Chief complaint
- [ ] Vital signs with timestamp
- [ ] Relevant medical history
- [ ] Current medications
- [ ] All tools used with results
- [ ] Assessment and plan
- [ ] Patient education provided
- [ ] Follow-up arrangements

---

## 3. Clinical Protocols

### 3.1 Hypertension Management Protocol

**Algorithm**: ACC/AHA 2017 Guidelines

```
BP Measurement → Classification → Risk Assessment → Management
     │               │                  │              │
     │               │                  │              ├─ <130/80: Lifestyle
     │               │                  │              │
     │               │                  │              ├─ 130-139/80-89:
     │               │                  │              │  Lifestyle + Risk-based
     │               │                  │              │  medication
     │               │                  │              │
     │               │                  │              └─ ≥140/90:
     │               │                  │         Lifestyle + 2-drug regimen
     │               │                  │
     ▼               ▼                  ▼
   Confirm        Stage        ASCVD Risk Score
   Diagnosis      + Target     + Comorbidities
```

**BP Targets**:
- General population: <130/80 mmHg
- Adults >65, DM, CKD: <130/80 mmHg (individualize)
- Pregnancy: Consult maternal-fetal medicine

**Medication Selection Guidelines**:
- First-line: Thiazide diuretic, CCB, ACEI/ARB
- Consider comorbidities (CKD → ACEI/ARB; DM → ACEI/ARB; CAD → BB)
- **⚠️ Medical Review Required**: Verify first-line choices

**Follow-up Schedule**:
- Normal: Recheck in 1 year
- Elevated: Recheck in 3-6 months
- Stage 1: Recheck in 1 month
- Stage 2: Recheck in 1 month (consider specialist)

---

### 3.2 Arrhythmia Assessment Protocol

**Scope**: Basic rhythm interpretation, not comprehensive EP management

**Red Flags Requiring Urgent Evaluation**:
- HR < 40 or > 150 bpm sustained
- Syncope or presyncope
- Chest pain with arrhythmia
- Hypotension with arrhythmia
- New-onset AF with rapid ventricular response (>110 bpm)
- Prolonged QTc > 500 ms

**QTc Prolongation Management**:
1. Review medications (stop QT-prolonging drugs)
2. Check electrolytes (K+, Mg++)
3. Evaluate for structural heart disease
4. Consider cardiology referral if >500 ms or symptomatic

**⚠️ Medical Review Required**:
- Verify QTc thresholds
- Confirm medication list accuracy
- Electrolyte replacement protocols

---

### 3.3 Cardiovascular Risk Assessment Protocol

**ASCVD Risk Calculation**:
- Age range: 40-75 years
- Exclusions: Known ASCVD, LDL >190, DM on medication
- Input requirements: All mandatory fields must be completed

**Risk Categories**:
- **Low** (<5%): Lifestyle counseling, repeat risk in 5 years
- **Borderline** (5-7.4%): Risk-enhancing factors, consider statin
- **Intermediate** (7.5-19.9%): Discuss moderate-intensity statin
- **High** (≥20%): High-intensity statin recommended

**Risk-Enhancing Factors**:
- Family history of premature ASCVD
- Elevated Lp(a)
- South Asian ancestry
- Chronic inflammatory conditions
- Women with premature menopause
- Other factors (per ACC/AHA guidelines)

---

### 3.4 Lipid Management Protocol

**Screening Recommendations**:
- Age 20-75: Every 4-6 years
- More frequent if: Risk factors, on statin therapy, cardiovascular events

**Statin Indications**:
| Age | ASCVD Risk | Recommendation |
|-----|------------|----------------|
| 40-75 | ≥7.5% | Moderate-intensity statin |
| 40-75 | ≥20% | High-intensity statin |
| 21-75 | LDL ≥190 | High-intensity statin |
| 40-75 | DM | Moderate-intensity statin |

**⚠️ Medical Review Required**:
- Verify statin intensity thresholds
- Side effect monitoring protocols
- Drug interaction considerations

---

## 4. Safety Protocols

### 4.1 Red Flag Symptoms

**Immediate Medical Attention Required**:
- Chest pain/discomfort (angina equivalent)
- Shortness of breath at rest
- Syncope or near-syncope
- Sudden severe headache
- Weakness/numbness (stroke symptoms)
- HR <40 or >150 sustained
- SBP >180 or DBP >120 with symptoms

### 4.2 Tool Limitations & Fail-Safes

**All Tools Must Include**:
- Clear indication of confidence level
- Known limitations
- When to recommend specialist consultation
- Disclaimer that tools are advisory only

**Example Disclaimer Template**:
```
This assessment is based on [GUIDELINE NAME] and is intended for
clinical decision support. Results should be interpreted in the
context of the complete clinical picture. This tool does not
replace clinical judgment. When in doubt, recommend specialist
consultation.
```

---

## 5. Quality Assurance

### 5.1 Tool Performance Monitoring

**Metrics to Track**:
- Tool usage frequency
- User satisfaction scores
- Clinical outcome correlation
- Adverse event detection
- Specialist referral rate

**Minimum Performance Standards**:
- [ ] To be defined by medical advisors
- [ ] Benchmark against standard of care

### 5.2 Clinical Decision Review

**Random Chart Review**:
- 10% of consultations reviewed monthly
- Focus on: Red flag recognition, appropriate referrals
- Standardized evaluation tool

**Adverse Event Review**:
- All adverse events reviewed within 7 days
- Root cause analysis performed
- Process improvement implemented

---

## 6. Communication Protocols

### 6.1 Patient Communication Standards

**Language Requirements**:
- Use plain language (health literacy 6th-8th grade level)
- Avoid medical jargon or explain when used
- Teach-back method to confirm understanding
- Provide written instructions when possible

**Risk Communication**:
- Use absolute risk (X out of 100) not relative risk
- Provide context for numbers
- Visual aids when appropriate
- Discuss uncertainty transparently

### 6.2 Inter-Professional Communication

**Referral Criteria** (to cardiology):
- Uncontrolled hypertension despite 2+ medications
- Complex arrhythmias requiring specialist management
- Known or suspected structural heart disease
- Pre-operative evaluation (high-risk surgery)
- Syncope of unknown etiology
- Chest pain with intermediate/high risk

**Documentation Standards**:
- Clear indication of reason for referral
- Summary of workup performed
- Specific question for consultant
- Relevant history and medications

---

## 7. Ethical Considerations

### 7.1 Equity and Bias

**Requirements**:
- Tools validated across diverse populations
- Race/ethnicity considerations documented
- Socioeconomic factors acknowledged
- Language access services available

### 7.2 Privacy and Data Security

**Patient Data Protection**:
- HIPAA compliance mandatory
- De-identification for AI systems
- Secure data storage and transmission
- Audit trail for all tool usage

### 7.3 Transparency

**Informed Disclosure**:
- Patients informed when AI tools are used
- Explanation of tool purpose available on request
- Option for human-only consultation

---

## 8. Emergency Protocols

### 8.1 Life-Threatening Emergencies

**Immediate Actions**:
1. Recognize emergency condition
2. Activate emergency response system
3. Do not rely on AI tools for emergency management
4. Document all actions

**Emergency Conditions**:
- Cardiac arrest
- STEMI
- Hypertensive emergency with end-organ damage
- Severe symptomatic bradycardia/tachycardia

---

## 9. Maintenance & Updates

### 9.1 Guideline Surveillance

**Responsibility**: Clinical lead cardiologist

**Process**:
- Quarterly guideline review
- Annual comprehensive update
- Trigger updates when major guidelines published

### 9.2 Version Control

**All policy documents must include**:
- Version number
- Effective date
- Review date
- Change log
- Approver signatures

---

## 10. Appendix

### 10.1 Quick Reference Guides

**Hypertension Classification Quick Reference**:
```
Normal: <120/<80
Elevated: 120-129/<80
Stage 1: 130-139/80-89
Stage 2: ≥140/≥90
Crisis: >180/>120 with symptoms
```

**QTc Thresholds**:
```
Normal: <440 ms (men), <450 ms (women)
Borderline: 440-469 ms
Prolonged: ≥470 ms (men), ≥480 ms (women)
Urgent: >500 ms or symptomatic
```

### 10.2 Contact Information

**Clinical Lead**: ______________________
**Medical Director**: ___________________
**On-Call Cardiologist**: _______________

### 10.3 Change Log

| Version | Date | Changes | Author | Reviewer |
|---------|------|---------|--------|----------|
| 1.0 | 2025-03-09 | Initial draft | AI System | ⚠️ Pending |

---

## 11. Review & Approval

### Required Signatures

**Clinical Governance**:
- [ ] Medical Director Review
- [ ] Cardiology Section Chief Review
- [ ] Quality Improvement Committee Approval
- [ ] Legal Review (liability considerations)
- [ ] Patient Safety Review

**Expert Review Panel**:
- [ ] Board-Certified Cardiologist #1
- [ ] Board-Certified Cardiologist #2
- [ ] Primary Care Physician Representative
- [ ] Clinical Pharmacist (if applicable)

**Reviewers must document**:
- Agreement with clinical content
- Identified concerns or modifications
- Recommended additions/deletions
- Overall approval status

---

**⚠️ STATUS: AWAITING MEDICAL EXPERT REVIEW**

**Next Steps**:
1. Distribute to cardiology review panel
2. Collect feedback within 30 days
3. Revise based on expert input
4. Final approval and implementation
5. Schedule next review (annually)

---

**Document Control**: This document is confidential and intended for use by authorized clinical personnel only.
